Database: French Epidemiological Strategy and Medical Economics Metastatic Breast Cancer (ESME-MBC) (France)
Go back to France page
Type of database: registry.
Primary purpose: To collect and analyze data related to metastatic breast cancer. This includes information on disease progression, treatments, prescriptions, biomarker data, and procedures, with the aim of improving understanding and outcomes in metastatic breast cancer treatment and medical economics.
Sponsor, manager, or home institution: Unicancer.
Type of information: longitudinal. It includes patient demographics (e.g., age, gender, menopausal status, weight), tumor characteristics (e.g., primary diagnosis, histology, relapses, ECOG performance status), treatments (e.g., drug names, administration routes, protocols, reasons for termination), clinical events (e.g., hospitalizations, procedures), biomarker data (e.g., gene alterations, HER2 status), and information on medicinal products (e.g., active ingredients, brand names). The database also captures cause of death, prescription and dispensing data for anti-cancer drugs, and is used for research and analysis on treatment patterns, patient outcomes, and disease progression in metastatic breast cancer. Click here to learn more.
Source of information: Electronic medical records (EMR) from 20 participating hospitals in France.
Data level: patient level.
Number of records: 38000.
Date range: 2014 onwards. Click here to learn more
Cancer areas of interest: C50: Breast cancer. Click here to learn more.
Data access: not publicly available. Data requires a grant proposal to be accessed. Instructions to request data for restricted content: Click here to access.
Contact information: Click here to learn more.
